Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts

Oral Oncology

Volumn 47, Issue 6, 2011, Pages 459-466

  Cao, Shousong ^a   Durrani, Farukh A ^a   Toth, Karoly ^a   Rustum, Youcef M ^a   Seshadri, Mukund ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Combination therapy; Head and neck cancer; Human tumor xenografts; Irinotecan; MRI

Indexed keywords

ALBUMIN GADOLINIUM PENTETATE MEGLUMINE; BEVACIZUMAB; IRINOTECAN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958034032     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.04.001     Document Type: Article

References (37)

1. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006;24(17):2603-5. (Pubitemid 46622079)
2. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8. (Pubitemid 37464533)
3. Folkman J. Angiogenesis. Ann Rev Med 2006;57:1-18 [Review].
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70. (Pubitemid 30046295)
5. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6(9):507-18 [Review].
6. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6(4):273-86 [Review].
7. Midgley R, Kerr D. Bevacizumab-current status and future directions. Ann Oncol 2005;16(7):999-1004 [Review].
8. Bozec A, Sudaka A, Fischel JL, Brunstein MC, Etienne-Grimaldi MC, Milano G. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer 2008;99(1):93-9. (Pubitemid 351920227)
9. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007;117(4):674-9. (Pubitemid 46559046)
10. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 2001;6(1):81-91. (Pubitemid 32155818)
11. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905-14.
12. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001;19(5):1501-18. (Pubitemid 32202559)
13. Murphy BA, Cmelak A, Burkey B, Netterville J, Shyr Y, Douglas S, et al. Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology 2001;15(7):47-52. (Pubitemid 33738945)
14. Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, et al. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008;113(1):186-92. (Pubitemid 351976400)
15. Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer. Cancer 2009;115(19):4504-13.
16. Cao S, McGuire JJ, Rustum YM. Antitumor activity of ZD1694 (Tomudex) against human head and neck cancer in nude mouse models: role of doing schedule and plasma thymidine. Clin Cancer Res 1999;5(7):1925-34. (Pubitemid 29334477)
17. Demsar F, Roberts TP, Schwickert HC, Shames DM, van Dijke CF, Mann JS, et al. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution. Magn Reson Med 1997;37(2):236-42. (Pubitemid 27045396)
18. Seshadri M, Merzianu M, Tang H, Rigual NR, Sullivan M, Loree TR, et al. Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol Ther 2009;8(23):2275-83.
19. Seshadri M, Toth K. Acute vascular disruption by 5,6-dimethylxanthenone- 4- acetic acid in an orthotopic model of human head and neck cancer. Transl Oncol 2009;2(3):121-7.
20. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by seleninum containing compounds against human tumor xenografts. Clin Cancer Res 2004;10(7):2561-9. (Pubitemid 38445719)
21. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattan S, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57.
22. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44. (Pubitemid 46733080)
23. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65(3):671-80. (Pubitemid 40216420)
24. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008 Feb;49(2):522-7.
25. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48(6):2545-52. (Pubitemid 351261204)
26. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400(1-3):83-106. (Pubitemid 28475097)
27. Masin JS, Berger SJ, Setrakian S, Stepnick DW, Berger NA. Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laryngoscope 1995;105(11):1191-6.
28. Yazici YD, Kim S, Jasser SA, Wang Z, Carter Jr KB, Bucana CD, Myers JN. Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope 2005 Dec;115(12):2249-55. (Pubitemid 44391644)
29. Gilbert J, Dang T, Cmelak A, Shyr Y, Netterville J, Burkey B, et al. Single agent irinotecan for the treatment of metastatic or recurrent squamous carcinoma of the head and neck (SCCHN). Clin Med Oncol 2007;1(7):67-71.
30. Koukourakis MI, Bizakis JG, Skoulakis CE, Kymizakis D, giatromanolaki A, Papadakis CE, et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 1999;19(3B):2305-9.
31. Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, et al. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007;18(1):47-51.
32. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-9. (Pubitemid 32937367)
33. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64(11):3731-6. (Pubitemid 38697278)
34. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59(14):3374-8. (Pubitemid 29334495)
35. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88(12):1979-86. (Pubitemid 36829677)
36. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, Wendland MF, et al. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008;247(2):391-9.
37. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27(15):2542-52.